Real-world evidence (RWE) is increasingly used by payers and providers to make informed, cost-effective decisions, linking policy changes to patient outcomes through claims, labs, and EMR data.124
Pharma companies leverage RWE to quantify payer policy impacts, such as step edits reducing market share by 12%, enabling better negotiations with payers and PBMs.2
ISPOR advances payer engagement via RWE initiatives, value assessment frameworks, and events focused on emerging trends in healthcare decision-making.3
Veradigm's RWE solutions support payer-provider collaborations for improved patient care, cost control, and regulatory requirements, with 1 in 2 FDA approvals in 2020 including RWE.4
A 2026 webinar highlighted payer data strategies using analytics for affordable, evidence-based care.5
Payer-sourced RWE accelerates biopharma R&D, regulatory readiness, and market access.6
Outcomes-based contracts using RWE, like a cardiovascular deal reducing hospital admissions by 22%, are scaling across therapeutic areas.7
Sources:
1. https://www.clinicaltrialsarena.com/sponsored/real-world-evidence-and-healthcare/
2. https://www.mmitnetwork.com/thought-leadership/tracking-real-world-impact-payer-policies-patient-outcomes/
3. https://www.ispor.org/strategic-initiatives/topics/payer-engagement-in-heor
4. https://veradigm.com/veradigm-news/real-world-evidence-solutions-payer-provider-collaborations/
5. https://www.wolterskluwer.com/en/expert-insights/healthcare-payer-analytics-and-data-strategies
6. https://www.fiercepharma.com/resource/harnessing-payer-sourced-real-world-data-accelerate-rd-and-market-access
7. https://www.simon-kucher.com/en/insights/innovation-revolutionizing-outcome-driven-payer-contracting-us-pharma-and-biotech